NTLA
Intellia Therapeutics Inc.
Is NTLA Halal?
In vivo CRISPR therapies — requires scholarly guidance.
What You Should Know
Develops gene editing inside the body. Its March 31, 2026 Form 10-Q reports $758.779 million of assets, $80.490 million of operating-lease liabilities, $134.697 million of cash, $382.550 million of marketable securities, $9.131 million of receivables and $15.048 million of quarterly revenue. Debt/assets is 10.61% and receivables-plus-cash/assets is 18.96%, but liquidity/assets is 68.16% and disclosed interest income is 34.59% of revenue. The examined financial screens fail; medical research is halal but gene editing technology requires scholar input.
⚠️ Concerns
- •Bioethics questions
- •Liquidity and income screens fail
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
80.49 / 758.779
517.247 / 758.779
143.828 / 758.779
5.205 / 15.048
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 68.16%, above the examined 33.333% limit, and disclosed interest income is 34.59% of revenue; debt/assets is 10.61% and receivables-plus-cash/assets is 18.96%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 68.16%, above the examined 33.33% limit; debt/assets and receivables-plus-cash remain below the examined limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 68.16%, above the examined Malaysia 33% limit; debt/assets is 10.61%. This calculation is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Intellia develops in-vivo CRISPR therapies. Therapeutic healthcare is generally permissible, while gene-editing boundaries, licensing and product allocation require qualified scholarly review.
Limitation: The filing does not provide a universal prohibited-activity numerator across collaborations and therapeutic programs.
Purification
Intellia discloses $5.205 million of interest income, but no scholar-approved purification percentage is asserted for the operating business.
Inputs, assumptions and primary sources
- Amounts are USD millions from Intellia Therapeutics' March 31, 2026 Form 10-Q.
- Conservative debt is the $80.490 million current and noncurrent operating-lease liability; no separate interest-bearing borrowing is tagged in the filing facts.
- Cash and cash equivalents are $134.697 million, current and noncurrent available-for-sale debt securities total $382.550 million and accounts receivable are $9.131 million.
- Quarterly collaboration revenue is $15.048 million and disclosed interest income is $5.205 million, or 34.59% of revenue.
- In-vivo gene-editing therapeutics are generally permissible in the retained qualitative analysis, but bioethics, clinical risk and program allocation require qualified scholarly review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →